References
- Chan K, Lo AC, Yeung JH, Woo KS. (1995). The effects of Danshen (Salvia miltiorrhiza) on warfarin pharmacodynamics and pharmacokinetics of warfarin enantiomers in rats. J Pharm Pharmacol 47:402–6
- Chu Y, Zhang L, Wang XY, et al. (2011). The effect of Compound Danshen Dripping Pills, a Chinese herb medicine, on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Ethnopharmacol 137:1457–61
- Dong RH, Fang ZZ, Zhu LL, et al. (2012). Investigation of UDP-glucuronosyltransferases (UGTs) inhibitory properties of carvacrol. Phytother Res 26:86–90
- Evans WE, Relling MV. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science 286:487–91
- Fang JL, Beland FA, Doerge DR, et al. (2002). Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Res 62:1978–86
- Fang ZZ, Zhang YY, Ge GB, et al. (2010). Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine–warfarin interaction. Br J Clin Pharmacol 69:193–9
- Fang ZZ, Zhang YY, Wang XL, et al. (2011). Bioactivation of herbal constituents: Simple alerts in the complex system. Expert Opin Drug Metab Toxicol 7:989–1007
- Huang T, Fang ZZ, Yang L. (2010). Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-glucuronosyltransferase (UGT) 2B7 might induce drug–drug interactions. Pharmazie 65:919–21
- King CD, Rios GR, Green MD, Tephly TR. (2000). UDP-glucuronosyltransferases. Curr Drug Metab 1:143–61
- Lai L, Hao H, Wang Q, et al. (2009). Effect of short-term and long-term pre-treatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 37:2399–407
- Li XX, Zhou ZW, Zhou SF. (2008). Role of P-glycoprotein in the transport of tanshinone I, one active triterpenoid from Salvia miltiorrhiza. Drug Metab Lett 2:223–30
- Lu PH, Chen MB, Wu XY, et al. (2011). Genetic polymorphisms of UGT1A7 and cancer risk: Evidence from 21 case-control studies. Cancer Invest 29:645–54
- Lu T, Yang J, Gao X, et al. (2008). Plasma and urinary tanshinol from Salvia miltiorrhiza (Danshen) can be used as pharmacokinetic markers for cardiotonic pills, a cardiovascular herbal medicine. Drug Metab Dispos 36:1578–86
- Meza-Junco J, Chu QS, Christensen O, et al. (2009). UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 65:1–4
- Qiu F, Zhang R, Sun J, et al. (2008). Inhibitory effects of seven components of danshen extract on catalytic activity of cytochrome P450 enzyme in human liver microsomes. Drug Metab Dispos 36:1308–14
- Ritter JK. (2000). Roles of glucuronidation and UDP-glucuronosyltransferases in xenobiotic bioactivation reactions. Chem Biol Interact 129:171–93
- Tan ML, Lim LE. (2014). The effects of Andrographis paniculata (Burm.f.) Nees extract and diterpenoids on the CYP450 isoforms' activities, a review of possible herb–drug interaction risks. Drug Chem Toxicol 26:1–13
- Tukey RH, Strassburg CP. (2000). Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581–616
- Wang Q, Hao H, Zhu X, et al. (2010a). Regioselective glucuronidation of tanshinone iia after quinone reduction: Identification of human UDP-glucuronosyltransferases, species differences, and interaction potential. Drug Metab Dispos 38:1132–40
- Wang X, Morris-Natschke SL, Lee KH. (2007). New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev 27:133–48
- Wang X, Cheung CM, Lee WY, et al. (2010b). Major tanshinones of Danshen (Salvia miltiorrhiza) exhibit different modes of inhibition on human CYP1A2, CYP2C9, CYP2E1 and CYP3A4 activities in vitro. Phytomedicine 17:868–75
- Wang X, Lee WY, Or PM, Yeung JH. (2010c). Pharmacokinetic interaction studies of tanshinones with tolbutamide, a model CYP2C11 probe substrate, using liver microsomes, primary hepatocytes and in vivo in the rat. Phytomedicine 17:203–11
- Zucker SD, Qin X, Rouster SD, et al. (2001). Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671–6